Previously recorded as BeiGene Switzerland GmbH (to 2025)
83 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2031. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2031
Next term end
53
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2037 · High confidence
Also notable
Ends Sep 2033 · High confidence
Also notable
Ends Apr 2033 · Low confidence
Also notable
Ends Sep 2036 · High confidence
Also notable
Ends Aug 2038 · High confidence
Also notable
Ends May 2039 · High confidence
Also notable
Ends Jun 2039 · High confidence
Also notable
Ends Oct 2038 · High confidence
Crystalline Form of (S)-7-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof
US 10,927,117
Cited by 36 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2037.
ANTI-PD1 Antibodies and Their Use as Therapeutics and Diagnostics
US 8,735,553
The most cited patent in this portfolio, cited by 269 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2033.
SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS
US 11,142,528
Cited by 34 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
ANTI-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics
US 11,512,132
Cited by 21 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
BTK Inhibitors with Improved Dual Selectivity
US 11,377,449
Cited by 23 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2038.
Treatment of Indolent or Aggressive B-Cell Lymphomas Using a Combination Comprising BTK Inhibitors
US 11,786,529
Cited by 19 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2039.
Treatment of B Cell Cancers Using a Combination Comprising BTK Inhibitors and Obinutuzumab
US 11,701,357
Cited by 18 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2039.
ANTI-TIM-3 Antibodies and Use Thereof
US 11,203,637
Cited by 14 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2038.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 13, 2026The maintenance fee for ANTI-PD1 Antibodies and Their Use as Therapeutics and Diagnostics (US 11,673,951) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 2 fees due Jan 16 to 18, 2027 · next Jan 16
- 1 fee due Feb 15, 2027The maintenance fee for IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS (US 11,725,012) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 3 fees due Apr 17 to 29, 2027 · next Apr 17
- 1 fee due May 14, 2027The maintenance fee for CRYSTALLINE FORM OF (S)-7-(1-Acryloylpiperidin-4-YL)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-Carboxamide, PREPARATION, AND USES THEREOF (US 11,814,389) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 4 fees due Jun 10 to 30, 2027 · next Jun 10
- 2 fees due Jul 28 to 30, 2027 · next Jul 28
- 6 fees due Aug 13 to 27, 2027 · next Aug 13
- 2 fees due Sep 1 to 3, 2027 · next Sep 1
- 1 fee due Oct 30, 2027The maintenance fee for CRYSTALLINE FORM OF (S)-7-(1-Acryloylpiperidin-4-YL)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-Carboxamide, PREPARATION, AND USES THEREOF (US 11,970,500) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
- 2 fees due Nov 3 to 12, 2027 · next Nov 3
Recent changes
- Nov 3Assignment recorded on 1 record: Wang, Qiuwen and 2 others to Beone Medicines I GmbH Recorded Nov 3, 2026, executed Mar 18, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76609, frame 655.
- 5 of the patents on this record were granted since Aug 23, 2026
- 1 term has ended since Aug 23, 2026
- Oct 30 US 10,112,952 Fused Tetra or Penta-Cyclic Dihydrodiazepinocarbazolones as Parp Inhibitors · lapsed on the fee record
What they patent
The largest of its 53 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,260,440 | Fused Tetra or Penta-Cyclic Dihydrodiazepinocarbazolones as Parp Inhibitors In force · High confidence | In force | High confidence | |
| US 9,273,046 | Fused Tricyclic Compounds as Raf Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,328,111 | SUBSTITUTED CYCLOOCTA[5,6]PYRIDO[4,3,2-de]PHTHALAZINES AS PARP INHIBITORS In force · High confidence | In force | High confidence | |
| US 9,895,376 | Fused Tricyclic Compounds as Raf Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 10,501,467 | Fused Tetra or Penta-Cyclic Dihydrodiazepinocarbazolones as Parp Inhibitors In force · High confidence | In force | High confidence | |
| US 10,576,087 | Fused Tricyclic Compounds as Raf Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,447,106 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS In force · High confidence | In force | High confidence | |
| US 10,005,782 | Substituted Pyrazolo[1,5-a]pyrimidines as Bruton's Tyrosine Kinase Modulators In force · Low confidence | In force | Low confidence | |
| US 10,570,139 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS In force · Low confidence | In force | Low confidence | |
| US 11,142,528 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 83: 2 patents ended · 119 applications pending · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.